Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 29 points (0.2%) at 17,603 as of Monday, Nov. 10, 2014, 12:00 PM ET. The NYSE advances/declines ratio sits at 1,659 issues advancing vs. 1,296 declining with 183 unchanged. The Diversified Services industry currently sits up 0.3% versus the S&P 500, which is up 0.3%. On the negative front, top decliners within the industry include SBA Communications ( SBAC), down 1.1%, and AerCap Holdings ( AER), down 0.9%. Top gainers within the industry include Amerco ( UHAL), up 1.6%, McGraw Hill Financial ( MHFI), up 0.7%, Thomson Reuters ( TRI), up 0.8% and Fiserv ( FISV), up 0.7%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Myriad Genetics ( MYGN) is one of the companies pushing the Diversified Services industry lower today. As of noon trading, Myriad Genetics is down $1.20 (-3.4%) to $33.69 on average volume. Thus far, 514,393 shares of Myriad Genetics exchanged hands as compared to its average daily volume of 805,200 shares. The stock has ranged in price between $32.81-$34.20 after having opened the day at $33.80 as compared to the previous trading day's close of $34.89. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive, personalized, and prognostic medicine tests in the United States and internationally. Myriad Genetics has a market cap of $2.5 billion and is part of the services sector. Shares are up 66.3% year-to-date as of the close of trading on Friday. Currently there are 4 analysts that rate Myriad Genetics a buy, 2 analysts rate it a sell, and 6 rate it a hold. TheStreet Ratings rates Myriad Genetics as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Myriad Genetics Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.